CN1512880A - 作为组织蛋白酶抑制剂的新型化合物和组合物 - Google Patents
作为组织蛋白酶抑制剂的新型化合物和组合物 Download PDFInfo
- Publication number
- CN1512880A CN1512880A CNA02811289XA CN02811289A CN1512880A CN 1512880 A CN1512880 A CN 1512880A CN A02811289X A CNA02811289X A CN A02811289XA CN 02811289 A CN02811289 A CN 02811289A CN 1512880 A CN1512880 A CN 1512880A
- Authority
- CN
- China
- Prior art keywords
- methyl
- alkyl
- sulfonyl
- group
- cyanogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/25—Aminoacetonitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29574401P | 2001-06-04 | 2001-06-04 | |
| US60/295,744 | 2001-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1512880A true CN1512880A (zh) | 2004-07-14 |
Family
ID=23139064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA02811289XA Pending CN1512880A (zh) | 2001-06-04 | 2002-06-04 | 作为组织蛋白酶抑制剂的新型化合物和组合物 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1399146A4 (sr) |
| JP (1) | JP2005500275A (sr) |
| KR (1) | KR20040028769A (sr) |
| CN (1) | CN1512880A (sr) |
| BR (1) | BR0210172A (sr) |
| CA (1) | CA2449021A1 (sr) |
| CO (1) | CO5540292A2 (sr) |
| EA (1) | EA007334B1 (sr) |
| HR (1) | HRP20031092A2 (sr) |
| IL (1) | IL159135A0 (sr) |
| MX (1) | MXPA03011207A (sr) |
| NO (1) | NO20035365L (sr) |
| NZ (1) | NZ529903A (sr) |
| PL (1) | PL368825A1 (sr) |
| RS (1) | RS96203A (sr) |
| SG (1) | SG143979A1 (sr) |
| WO (1) | WO2002098406A1 (sr) |
| ZA (1) | ZA200309371B (sr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2848232B2 (ja) * | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
| PT1021424E (pt) * | 1996-06-21 | 2003-06-30 | Upjohn Co | Amidas de tiadiazolo como inibidores da metaloproteinase de matriz |
| EP1212302A1 (en) * | 1999-09-16 | 2002-06-12 | Axys Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions as cathepsin s inhibitors |
-
2002
- 2002-06-04 BR BR0210172-6A patent/BR0210172A/pt not_active IP Right Cessation
- 2002-06-04 SG SG200600505-2A patent/SG143979A1/en unknown
- 2002-06-04 PL PL02368825A patent/PL368825A1/xx not_active Application Discontinuation
- 2002-06-04 MX MXPA03011207A patent/MXPA03011207A/es not_active Application Discontinuation
- 2002-06-04 NZ NZ529903A patent/NZ529903A/en unknown
- 2002-06-04 KR KR10-2003-7015837A patent/KR20040028769A/ko not_active Ceased
- 2002-06-04 JP JP2003501445A patent/JP2005500275A/ja active Pending
- 2002-06-04 EP EP02739721A patent/EP1399146A4/en not_active Withdrawn
- 2002-06-04 CA CA002449021A patent/CA2449021A1/en not_active Abandoned
- 2002-06-04 RS YU96203A patent/RS96203A/sr unknown
- 2002-06-04 IL IL15913502A patent/IL159135A0/xx unknown
- 2002-06-04 CN CNA02811289XA patent/CN1512880A/zh active Pending
- 2002-06-04 EA EA200301315A patent/EA007334B1/ru not_active IP Right Cessation
- 2002-06-04 WO PCT/US2002/017922 patent/WO2002098406A1/en not_active Ceased
- 2002-06-04 HR HR20031092A patent/HRP20031092A2/xx not_active Application Discontinuation
-
2003
- 2003-12-02 NO NO20035365A patent/NO20035365L/no not_active Application Discontinuation
- 2003-12-02 ZA ZA200309371A patent/ZA200309371B/en unknown
- 2003-12-30 CO CO03113269A patent/CO5540292A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20035365D0 (no) | 2003-12-02 |
| NO20035365L (no) | 2004-02-20 |
| WO2002098406A1 (en) | 2002-12-12 |
| RS96203A (sr) | 2006-12-15 |
| BR0210172A (pt) | 2004-06-22 |
| EA200301315A1 (ru) | 2004-06-24 |
| PL368825A1 (en) | 2005-04-04 |
| KR20040028769A (ko) | 2004-04-03 |
| MXPA03011207A (es) | 2004-02-26 |
| HRP20031092A2 (en) | 2004-04-30 |
| EP1399146A1 (en) | 2004-03-24 |
| IL159135A0 (en) | 2004-05-12 |
| JP2005500275A (ja) | 2005-01-06 |
| EA007334B1 (ru) | 2006-08-25 |
| NZ529903A (en) | 2005-09-30 |
| SG143979A1 (en) | 2008-07-29 |
| CA2449021A1 (en) | 2002-12-12 |
| EP1399146A4 (en) | 2006-01-18 |
| CO5540292A2 (es) | 2005-07-29 |
| ZA200309371B (en) | 2005-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1263755C (zh) | 作为选择性cox-2抑制剂的吡唑并吡啶衍生物 | |
| CN1159292C (zh) | 用作选择性多巴胺d3配体的芳基取代的环胺类化合物 | |
| CN1653047A (zh) | 抗炎症药物单环芳酰吡啶酮 | |
| CN1753884A (zh) | 阿片类受体拮抗剂 | |
| CN1088917A (zh) | 取代的苄氨基含氮非芳族杂环化合物 | |
| HK1041486A1 (zh) | 作為前列腺素e2激動劑或拮抗劑的噁唑化合物 | |
| CN1494527A (zh) | 邻位、间位取代的双芳基化合物、它们的制备方法、它们作为药物的用途和含有它们的药物制剂 | |
| CN1264382A (zh) | 新的化合物 | |
| CN1761646A (zh) | 大麻素受体配位体 | |
| CN1633416A (zh) | 用作p38抑制剂的烟酰胺衍生物 | |
| CN1040986A (zh) | 环烷基取代的戊二酰胺衍生物的制备 | |
| CN1305454A (zh) | 作为cgmp-磷酸二酯酶抑制剂的邻氨基苯甲酸衍生物 | |
| CN1545509A (zh) | 用作趋化因子受体活性调节剂的哌啶衍生物 | |
| CN1324008C (zh) | 作为组织蛋白酶抑制剂的新化合物和组合物 | |
| CN1859914A (zh) | 苯基吡咯烷醚速激肽受体拮抗剂 | |
| CN1910157A (zh) | 对受体cbi有亲和性的n′-(1,5-二苯基-1h-吡唑-3-基)磺酰胺衍生物 | |
| CN1512983A (zh) | 作为组织蛋白酶s抑制剂的化合物和组合物 | |
| HK1042691A1 (zh) | 磺酰胺异羟肟酸脂 | |
| CN1665503A (zh) | 杂芳烃甲酰胺作为多巴胺-d3配体用于治疗中枢神经系统疾病的用途 | |
| CN1205704A (zh) | 2,7-取代的八氢-吡咯并[1,2-a]吡嗪衍生物 | |
| CN1324018C (zh) | 作为组织蛋白酶s抑制剂的寡肽以及含有它们的组合物 | |
| CN1906154A (zh) | 氨基醇衍生物 | |
| CN1633291A (zh) | 2-噁唑胺及其作为5-ht2b受体拮抗剂的应用 | |
| CN1665506A (zh) | 作为ccr-3受体拮抗剂ⅸ的2,5-取代的嘧啶衍生物 | |
| CN1512880A (zh) | 作为组织蛋白酶抑制剂的新型化合物和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |